Comparative study on effect of R-CHOP regimen and CHOP regimen for the treatment of newly diagnosed patients with early-stage primary gastric diffuse large B-cell lymphoma

Objective To compare the effect and safety of rituximab plus CHOP (R-CHOP) and CHOP regimens for the treatment of newly diagnosed patients with early-stage primary gastric diffuse large B-cell lymphoma (PG-DLBCL). Methods A total of 65 patients with PG-DLBCL were retrospectively divided into two groups: 35 patients were treated with R-CHOP regimen, the others with CHOP regimen. NHL international efficacy assessment and WHO criteria were used to assess the therapeutic and the adverse reactions respectively. Results The complete remission(CR) rate of R-CHOP group was 74.3 % (26/35), which was significantly higher than that of CHOP group [50.0 % (15/30), P 0.05). The Kaplan-Meier survival analysis showed that the five-year survival rates of two groups had no significant difference (88.6 % vs 75.0 %, P> 0.05). The PFS of R-CHOP group was better than that of CHOP group (94.4 months vs 74.9 months, P< 0.05). Conclusion Compared with CHOP regimen, R-CHOP regimen increases the therapeutic efficacy in patients with PG-DLBCL, and dose not increase the adverse reactions. Key words: Stomach neoplasms; Lymphoma, large B-cell, diffuse; Antineoplastic combined chemotherapy protocols